NEWSROOM
News & Stories
Newsroom
Press Releases
German Gynecological Oncology Group (AGO) Acknowledges MammaPrint in Breast Cancer Guidelines as Having Level 1A Clinical Evidence
2017 Guidelines of the AGO Breast Committee acknowledges Agendia’s MammaPrint test with highest medical evidence level 1A for identification of patient subgroups who can potentially forgo chemotherapy for breast cancer IRVINE, CA and AMSTERDAM – Read More
Agendia Co-Founder Laura van ‘t Veer Wins European Cancer Organization Clinical Research Award
Significant clinical benefit of Agendia’s MammaPrint® test and other advances in the improved treatment of breast cancer recognized at ceremony during ECCO2017 IRVINE, CA and AMSTERDAM – 30 January 2017 – Agendia, Inc., a world Read More
New Data Shows that MammaPrint Substantially Impacts how Breast Cancer Patients in Germany are Treated
PRIMe trial included 452 women at 27 centers in Germany, Austria, and Switzerland Based on the outcome of the MammaPrint test, 28.4% of patients’ treatment plans were changed, compared to conventional clinico-pathological tests; preventing under Read More







